Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid ...
The role of PCSK9 inhibitors as treatment for dyslipidemia now that statin therapies are available. Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to ...
Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...
New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | ...
In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...
Although some of the barriers that have kept cholesterol-lowering PCSK9 inhibitors out of reach for many patients in the United States have eased a bit in recent years, a new analysis suggests that ...
The upregulation of PCSK9 expression in endothelial cells of diabetic patients induces ubiquitination of VEGFR2 and inhibits the VEGFR2/ AKT/eNOS -ERK signaling pathway by promoting the interaction of ...
Please provide your email address to receive an email when new articles are posted on . MIAMI — Significant additional lipid lowering occurred during a 2-month period in patients assigned bempedoic ...
ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...
Please provide your email address to receive an email when new articles are posted on . In heart transplant recipients, PCSK9 inhibitors lowered LDL, stabilized coronary intimal hyperplasia and were ...
For those who play the high-stakes game of drug discovery, cholesterol-lowering PCSK9 inhibitors don’t seem anything like a sure bet. Patients will need to inject the drugs. They’re likely to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback